First of all, it's completely understandable to feel worried — starting a new treatment while managing heart failure is a lot to take on. The concern is valid, and it's good to be asking these questions ahead of time.
Here's what's generally known about DRd (Daratumumab, Lenalidomide, Dexamethasone) and heart health:
Show Full Answer
First of all, it's completely understandable to feel worried — starting a new treatment while managing heart failure is a lot to take on. The concern is valid, and it's good to be asking these questions ahead of time.
Here's what's generally known about DRd (Daratumumab, Lenalidomide, Dexamethasone) and heart health:
Daratumumab is a monoclonal antibody. Its most notable risks include infusion reactions, which can include throat tightness, wheezing, dizziness, and breathing difficulty — especially during or shortly after the infusion. These are monitored closely during treatment.
Lenalidomide is an immunomodulator. One important concern for someone with heart failure is that it can increase the risk of blood clots in the veins or lungs. Given that aspirin is already part of the current medication list, the care team may already be factoring in clot prevention.
Dexamethasone is a corticosteroid that can raise blood pressure and blood sugar levels, both of which are worth monitoring carefully alongside existing heart medications. With the current medication list — which includes heart-specific drugs like Bisoprolol, Eplerenone, Candesartan, and Bumetanide — the myeloma care team will need to work closely with a cardiologist. This kind of collaboration is really important to:
- Monitor heart function regularly during treatment
- Watch for fluid retention (some myeloma drugs can worsen this)
- Adjust medications if blood pressure or heart rhythm changes
- Keep an eye on blood clot risk with Lenalidomide
It's worth asking the oncologist directly: *"Will my cardiologist be involved in monitoring me during DRd treatment?"* and *"Will any of my current heart medications need to be adjusted?"*
Some MyMyelomaTeam members have shared that their medication lists were reviewed and sometimes adjusted when starting new myeloma treatments, particularly when heart conditions were involved.
The care team starting this treatment will be aware of these risks — they wouldn't proceed without weighing the benefits carefully. Going in with a list of questions is one of the best things that can be done right now. 💙
June 10